Durable response to afatinib in an advanced lung adenocarcinoma patient with an EGFR L858R/G729A compound mutation: a case report

Of the epidermal growth factor receptor (EGFR) mutations in patients with non-small cell lung cancer (NSCLC), 10–15% are uncommon mutations. Most of the EGFR “major” uncommon mutations have shown responses to EGFR-tyrosine kinase inhibitors (TKIs). However, there is a lack of clinical data for other...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Lige, Fang, Cheng, Zhao, Weiqing, Li, Dong, Tang, Shuxian, Li, Xi, Ji, Mei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848381/
https://www.ncbi.nlm.nih.gov/pubmed/35282062
http://dx.doi.org/10.21037/atm-22-95

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848381/
https://www.ncbi.nlm.nih.gov/pubmed/35282062
http://dx.doi.org/10.21037/atm-22-95

Ejemplares similares